Beijing, CARTITUDE-4, CARVYKTI, China, ciltacabtagene autoleucel, Clinical trials, Legend biotech, refractory multiple myeloma, Shanghai
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI®(ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
JANUARY 27, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that ..
Beijing, Biotechnology, Cell therapy, Cellular therapy, China, Cilta-Cel, ciltacabtagene autoleucel, Legend biotech
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
SOMERSET, N.J.—JANUARY 2, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, ann..
American Society of Hematology, Carteyva, China, JW Therapeutics, relmacabtagene autoleucel
JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting
SHANGHAI, CHINA, December 12, 2022 An independent and creative biotechnology company called JW Therapeutics (HKEX: 2126) focuses on developing, manufacturing, and selling cell immunotherapy products. At the 64th American Society ..
Cell therapy, China, JW Therapeutics, Shanghai
JW Therapeutics Announces That Its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients
SHANGHAI, CHINA, November 9, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that as of N..
2seventy bio, China, Immunotherapy, JW Therapeutics, Partnership
JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T-cell-based Immunotherapies
SHANGHAI, CHINA and CAMBRIDGE, MASSACHUSETTS, US, October 27, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherap..
Carteyva, JW Therapeutics, lymphoma, refractory follicular lymphoma, RELIANCE study, relmacabtagene autoleucel
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that the Na..
BRL Biotech, CAR T-Cell, CARsgen Therapeutics, China CAR T Cell, IASO Biotherapeutics, Juventas Therapeutics, Relma-cel
How China is leading the development of CAR T-Cell therapy?
March 2023: CAR-T-cell therapy is a novel and effective cancer treatment modality that has revolutionized the treatment of cancer, particularly blood cancers. This therapy achieves a therapeutic effect or cures disease by repairi..
CAR19, CARGO, CD19, CD22, CRG-022, Gina Chapman, Third Rock Ventures
Cargo, a cancer drug startup, raises $200 million to combat CAR-T relapse
March 2023: Several types of lymphoma, as well as certain leukaemias and multiple myeloma, can now be effectively treated with CAR-T therapy. Recent studies have demonstrated the efficacy of CAR-T therapy at an earlier stage, res..
CAR - T Cell therapy, CAR T-Cell, Emily Littlejohn, Immunology, lupus renaissance
New CAR T-Cell therapy drug in lupus renaissance
Feb 2024: Several new drugs and promising therapies, such as chimeric antigen receptor T-cell therapy, have ushered in a "renaissance" for lupus, according to a speaker at the symposium Basic and Clinical Immunology for the Busy ..
Bruce Levine, CAR-T therapies, Carl June, Gilead, Kite, Tmunity Therapeutic, University of Pennsylvania
Kite completes acquisition of Tmunity
Press Release Feb 2023: - Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech compan..